$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
肝癌靶向药索拉非尼有耐药性吗?
2025-10-19 11:44:20
Check Details
肝癌服用多吉美多长时间复查?多吉美吃多久有效果?
2025-10-19 11:44:20
Check Details
【患者须知】肝癌患者服用乐伐替尼的禁忌和注意事项
2025-10-19 11:44:20
Check Details
肝癌晚期吃乐伐替尼可以缩小肿瘤吗?
2025-10-19 11:44:20
Check Details
多吉美在国内医保报销条件
2025-10-19 11:44:20
Check Details
早期肝癌可以用乐伐替尼进行治疗吗?
2025-10-19 11:44:20
Check Details
多吉美耐药后接下来换什么靶向药?
2025-10-19 11:44:20
Check Details
索拉非尼治疗肝癌一个月的费用是多少?
2025-10-19 11:44:20
Check Details
肝癌晚期服用多吉美的禁忌和注意事项
2025-10-19 11:44:20
Check Details
乐伐替尼2021年进医保后可以报销多少?
2025-10-19 11:44:20
Check Details
【关注】多吉美医保报销后的最新价格
2025-10-19 11:44:20
Check Details
肝癌靶向药乐伐替尼医保报销比例
2025-10-19 11:44:20
Check Details
1
2
...
2873
2874
2875
2876
2877
2878
2879
...
4155
4156
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice
2
Managing Amivantamab Infusion Reactions: A Clinical Guide for International Practice
3
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
4
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
5
Vemurafenib (Zelboraf) Complete Medication Guide
6
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice
7
Zolbetuximab Combination Therapy: Global Efficacy and Safety Profile in CLDN18.2-Positive Advanced Gastric Cancer
8
Managing Mitotane Resistance in Adrenocortical Carcinoma: Strategies and Global Options
9
Trametinib & Dabrafenib in 2026: A Global Guide to Treating BRAF-Mutant Cancers
10
A Guide to Safely Stopping Mitotane: Why Tapering is Essential and How to Manage
11
Pemigatinib Efficacy: Significantly Improving Survival in FGFR2-Fusion Cholangiocarcinoma
12
Erlotinib: Targeting EGFR Mutations to Precisely Inhibit Non-Small Cell Lung Cancer Growth